Originally published In Press as doi:10.1074/jbc.M001705200 on May 8, 2000
J. Biol. Chem., Vol. 275, Issue 31, 24222-24230, August 4, 2000
A 54-kDa Fragment of the Poly(A)-specific Ribonuclease
Is an Oligomeric, Processive, and Cap-interacting
Poly(A)-specific 3' Exonuclease*
Javier
Martínez
§,
Yan-Guo
Ren
§,
Ann-Charlotte
Thuresson
,
Ulf
Hellman¶,
Jonas
Åström
, and
Anders
Virtanen
**
From the
Department of Cell and Molecular Biology,
Uppsala University, Box 596, SE-751 24 Uppsala, Sweden, the
¶ Ludwig Institute for Cancer Research, Box 595, SE-751 24 Uppsala, Sweden, and
Amersham Pharmacia Biotech, Box 605, SE-751
25 Uppsala, Sweden
Received for publication, February 25, 2000, and in revised form, April 17, 2000
 |
ABSTRACT |
We have previously identified a HeLa cell 3'
exonuclease specific for degrading poly(A) tails of mRNAs. Here we
report on the purification and identification of a calf thymus 54-kDa
polypeptide associated with a similar 3' exonuclease activity. The
54-kDa polypeptide was shown to be a fragment of the poly(A)-specific ribonuclease 74-kDa polypeptide. The native molecular mass of the nuclease activity was estimated to be 180-220 kDa. Protein/protein cross-linking revealed an oligomeric structure, most likely consisting of three subunits. The purified nuclease activity released 5'-AMP as
the reaction product and degraded poly(A) in a highly processive fashion. The activity required monovalent cations and was dependent on
divalent metal ions. The RNA substrate requirement was investigated, and it was found that the nuclease was highly poly(A)-specific and that
only 3' end-located poly(A) was degraded by the activity. RNA
substrates capped with m7G(5')ppp(5')G were more
efficiently degraded than noncapped RNA substrates. Addition of free
m7G(5')ppp(5')G cap analogue inhibited poly(A) degradation
in vitro, suggesting a functional link between the RNA 5'
end cap structure and poly(A) degradation at the 3' end of the RNA.
 |
INTRODUCTION |
In recent years it has become clear that poly(A) removal is an
important step during mRNA decay, and it has been found that mRNA degradation in many cases is initiated by degrading the
mRNA poly(A) tail (reviewed in Ref. 1). In yeast two major
deadenylation-dependent pathways of mRNA degradation
have been defined, the deadenylation-dependent decapping
pathway and the 3'-5' decay pathway (for reviews see Refs. 2 and 3).
The former pathway is initiated by poly(A) tail removal followed by
decapping and 5'-3' exonucleolytic degradation of the decapped mRNA
by the Xrn1p 5' exonuclease. The latter is initiated by deadenylation
followed by 3'-5' exoribonucleolytic degradation of the mRNA. The
participating 3'-5' exonucleases have not yet been unambiguously
identified. A multicomponent complex, termed the exosome (4), has been
identified in yeast as well as in human cells, and it contains at least
10 different 3'-5' exoribonucleases (reviewed in Ref. 5). The exosome
is involved in 3' end processing of several different stable RNAs (4,
6) and 3'-5' degradation of mRNA (7). Thus, these exoribonucleases could be responsible for the degradation of mRNA including the poly(A). However, it remains to be established whether any of these
exonucleases preferentially or exclusively degrade poly(A) of mRNA.
In mammalian cells mRNA decay has been studied extensively, and it
has been found that gene expression to a large extent is regulated by
changing the stability of an mRNA. From these studies it has been
shown that cis-acting elements located in the mRNA body
are important elements involved in regulating mRNA decay. One of
the first elements to be identified was an AU-rich element located in
the 3'-untranslated region of the human lymphokine granulocyte
macrophage colony-stimulating factor mRNA (8). Shaw and Kamen (8)
showed that the AU-rich element destabilized an mRNA and that the
element could confer the destabilization effect if it was transferred
to another mRNA. Furthermore, it has been found, equivalent to the
case in yeast, that mRNA decay in mammalian cells in many cases is
initiated by poly(A) removal (9). However, most of these studies (1)
have been performed in vivo, and therefore, it has been
difficult to identify participating components and to address
mechanistic details. In the last years several in vitro
cell-free mRNA stability systems have been developed, and these
systems will make it possible to elucidate mechanistic details and to
identify factors regulating mRNA decay in mammalian cells (10-14).
Using such a system Wilusz and colleagues (13) have been able to
stimulate poly(A) removal and RNA degradation by the presence of an
AU-rich sequence element (8) in the RNA body and to reproduce regulated
aspects of mRNA decay. Similarly, Brewer (11) has shown that the
3'-untranslated region of c-Myc affects poly(A) removal and RNA
degradation in a different in vitro system. The
poly(A)-specific exonucleases responsible for degrading the mRNA
poly(A) tails in these in vitro decay systems remains to be identified.
Poly(A) tail removal and poly(A) degrading nuclease activities have
been studied in several eukaryotic systems (for reviews see Refs. 1, 3,
and 15). In mammalian cells several different poly(A) degrading
activities have been characterized over the years. Earlier studies
(reviewed in Ref. 16) were hampered by the lack of RNA substrates
resembling polyadenylated mRNA, making it difficult to assay,
purify, and characterize nucleases that specifically degraded only the
poly(A) tail of an mRNA. By the use of an in vitro
transcribed and polyadenylated mRNA mimic we were able to define a
poly(A)-specific 3' exonuclease in HeLa cell free extracts (17) and
propose a reaction pathway for mRNA poly(A) tail removal (18).
Important properties of the HeLa cell activity were its high
selectivity for degrading only 3'-located poly(A) tails, its
requirement for a 3'-located hydroxyl group, and release of 5'-AMP as
the mononucleotide product. Recently, a poly(A)-specific ribonuclease
(PARN)1 associated with a
74-kDa polypeptide was purified and characterized in calf thymus
extracts by Körner and Wahle (19). Human PARN has been
molecularly cloned, and PARN activity has been recovered from
recombinant 74-kDa polypeptide (20). PARN has also been found in
Xenopus and shown to play a role in poly(A) tail removal during meiotic maturation of Xenopus oocytes (20, 21). A
polyribosome-associated 3' exoribonuclease, having a molecular mass of
33 kDa has been described and purified by Caruccio and Ross (22).
However, this 3' exoribonuclease is not specific for poly(A), although
poly(A) can be degraded. In addition to these metazoan poly(A)
degrading nucleases Sachs and colleagues have described a
poly(A)-binding protein-dependent poly(A)-specific nuclease
in yeast (23-25). Poly(A)-specific nuclease is a 3'-5' exoribonuclease
and is composed of at least two polypeptides, Pan2p and Pan3p (26, 27).
Pan2p contains a conserved RNase D 3' exonuclease domain (28),
suggesting that it harbors the catalytic activity.
In this paper we report on the purification of an activity present in
calf thymus extracts having the same properties as the poly(A)
tail-specific 3' exonuclease activity we previously described in HeLa
cell free extracts (17, 18). The calf thymus activity has been purified
to apparent homogeneity and shown to copurify with a single
54-kDa polypeptide, which we identify as a fragment of the PARN 74-kDa
polypeptide. We show that the purified nuclease most likely is
oligomeric, acts in a highly processive fashion, and functionally
interacts with the m7G(5')ppp(5')G cap structure at the 5'
end of the RNA substrate.
 |
EXPERIMENTAL PROCEDURES |
Preparation of Cell-free Extracts--
All steps were performed
at 4 °C. Crude whole cell extract was prepared from bovine calf
thymus, essentially according to Wahle (29). In short, frozen
calf thymus (2-15 kg) obtained from a local slaughter house was thawed
on ice, cut into pieces, and homogenized in an approximately equal
volume of buffer 1 (50 mM Tris-HCl, 10 mM
K3PO4, 1 mM EDTA, 10% glycerol, 50 mM KCl, 0.1 mM dithiothreitol at pH 7.9) using
a Waring blender (50 s at low speed and 50 s at high speed). Solid
material was precipitated by centrifugation in a Sorvall GSA rotor at
16,000 × g in 4 °C for 60 min. The resulting crude
extract was filtered through a test sieve mesh 7-normal (Pascal Eng.
Co. Ltd.), 0.134 g/ml NH4(SO4)2 (25% saturation) was added and stirred on ice for 2 h, and the precipitate was removed by centrifugation in a Sorvall GSA rotor at
16,000 × g in 4 °C for 60 min. The supernatant was
further supplemented with an additional 0.115 g/ml
NH4(SO4)2 (45% saturation) and
then treated as for the previous precipitation step. The pellet collected after centrifugation was dissolved in 2-4 volumes buffer D
(20 mM HEPES-KOH, 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 20% glycerol at pH 8.2) and dialyzed
for 10 h at 4 °C using dialysis tubing with a molecular mass
cut-off at 6000-8000 (Spectra/Por 1 number 132650). After
dialysis the 45% ammonium sulfate fraction was frozen in liquid
nitrogen and stored at
70 °C. Starting with 2.8 kg of calf thymus
the obtained extract (~1038 ml) contained approximately 103 g of
protein. The subsequent ammonium sulfate fraction contained 13.7 g
of protein in 400 ml. Protein concentration was determined using the
Bio-Rad protein assay kit (number 500-0001) and bovine
globulin as reference.
Partial Purification of Poly(A)-specific 3' Exonuclease
Activity--
All steps were performed at 4 °C. A typical protocol
starting with 400 ml of crude ammonium sulfate fraction (13.7 g of
protein) is given below and summarized in Table I. The ammonium sulfate fraction was added to DEAE-Sepharose CL-6B (Amersham Pharmacia Biotech,
17-0710-01) ion exchange medium (350 ml of packed matrix) equilibrated
with buffer D (see above). Protein was allowed to bind to the matrix
under slow stirring for 30 min at 4 °C. Unbound material was removed
by washing the matrix with buffer D three times. The suspended matrix
was recovered by centrifugation (Sorvall H4000 rotor at 800 rpm for 3 min) after each washing step. The washed matrix was then packed in a
column (diameter, 70 mm) and washed (2 column volumes) with buffer D at
a flow rate of 12 cm/h. The column was eluted by two salt steps (buffer
D supplemented with 0.17 M and 1.0 M KCl), and
eluted protein from each step was collected. The nuclease activity,
which eluted in the 0.17 M KCl step fraction (1.67 g of
protein, 440 ml), was dialyzed against buffer D for 10 h and
subsequently fractionated by heparin-Sepharose CL-6B (Amersham
Pharmacia Biotech, 17-0467-01) chromatography. A column with bed volume
of 130 ml and a diameter of 50 mm was equilibrated with buffer D at
flow rate 9 cm/h. The dialyzed DEAE-Sepharose 0.17 M KCl
fraction was applied to the heparin-Sepharose CL-6B column at a flow
rate of 9 cm/h. The flow through protein fraction was collected, and
then the matrix was washed with 350 ml of buffer D. The nuclease
activity was subsequently eluted by buffer D supplemented with 0.5 M KCl. The eluate (441 mg of protein, 96 ml) was dialyzed against buffer D for 10 h at 4 °C and subsequently fractionated by fast protein liquid chromatography Mono Q HR16/10 (Amersham Pharmacia Biotech, 17-0506-01) chromatography. Protein was loaded (~48 ml of 0.5 M KCl heparin-Sepharose fraction/turn)
onto the buffer D equilibrated Mono Q column using a 50-ml superloop
(Amersham Pharmacia Biotech, 19-7850-01) at flow rate 2 ml/min. After
washing with buffer D, the column was developed with a two-step linear gradient (0-25% in 300 ml and 25-55% in 100 ml of buffer D,
supplemented with 1.0 M KCl), 9-ml fractions were
collected, and active fractions (eluting at ~10% 1.0 M
KCl) were identified, pooled (81.8 mg of protein, 115 ml), and dialyzed
against buffer D for 10 h at 4 °C. A 36-ml packed
Blue-Sepharose CL-6B (Amersham Pharmacia Biotech, 17-0830-01) column,
26 mm in diameter, was prepared according to the instructions of the
manufacturer. The column was equilibrated with buffer D at a flow rate
of 34 cm/h. The Mono Q fraction (115 ml) was loaded onto the
column followed by a three-step wash procedure of the matrix (100 ml of
buffer D, 100 ml of buffer D supplemented with 0.17 M KCl,
and 100 ml of buffer D supplemented with 0.3 M KCl). The
column was developed with a linear gradient between 0.3 and 1.0 M KCl (4.5 column volumes). Active fractions were identified (eluting at ~0.45 M KCl), pooled (7.88 mg of
protein, 105 ml), and dialyzed against buffer D for 10 h at
4 °C. The dialyzed fraction was frozen in liquid nitrogen and stored
at
70 °C.
Poly(A)-Sepharose Affinity Chromatography--
All steps were
performed at 4 °C. A standard protocol is given below. The
poly(A)-Sepharose 4B matrix (Amersham Pharmacia Biotech, 17-0860-01)
was prepared according to the manufacturer. A HR10/10 column with bed
volume of 8 ml was equilibrated with buffer D containing 25 mM KCl at pH 7. 12 ml of the Blue-Sepharose CL-6B fraction
was dialyzed for 4 h against 2 × 2 liters of buffer D
containing 25 mM KCl at pH 7. The dialyzed fraction was
applied to the column at flow rate of 1 ml/min. The column was first
washed with 5 bed volumes of buffer D containing 25 mM KCl
at pH 7 followed by a second wash with 5 bed volumes of buffer D
containing 200 mM KCl at pH 6 and a third wash with 5 bed
volumes of buffer D containing 280 mM KCl at pH 6. Subsequently, the column was developed with a gradient (5 bed volumes)
from 280 to 600 mM KCl at pH 6. Poly(A)-specific
exonuclease activity eluted between 300 and 550 mM KCl.
This procedure purifies the specific activity of the poly(A)-specific exonuclease approximately 14-fold.
5'-AMP-Sepharose and 7-Methyl-GTP-Sepharose Affinity
Chromatography--
All steps were performed at 4 °C. A standard
protocol is given below. The 5'-AMP-Sepharose 4B matrix (Amersham
Pharmacia Biotech, 17-0620-01) was prepared according to the
manufacturer. A HR 5/10 column (Amersham Pharmacia Biotech, 18-0388-01)
with bed volume of 2 ml was prepared and equilibrated with buffer D
containing 50 mM KCl at pH 7. The Blue-Sepharose CL-6B
fraction (27.5 ml) was dialyzed against buffer D supplemented with 50 mM KCl at pH 7. The dialyzed fraction was loaded on the
column at flow rate 0.2 ml/min. The protein containing flow through
fraction was collected. The matrix was washed with 16 ml of buffer D
supplemented with 60 mM KCl followed by a 20-ml wash with
buffer D supplemented with 0.3 M KCl. Subsequently the
column was developed with buffer D using a linear gradient between
0.3-2.0 M KCl (7.5 column volumes). Active fractions
(eluting between 0.7-2.0 M KCl) were identified, pooled
(15 ml), and dialyzed against buffer D. The matrix
7-methyl-GTP-Sepharose 4B (Amersham Pharmacia Biotech, 27-5025-01) was
prepared according to the manufacturer. A HR 5/5 column (Amersham
Pharmacia Biotech, 18-0383-01) with bed volume of 1 ml was prepared and
equilibrated with buffer D containing 50 mM KCl at pH 7. The dialyzed 5'-AMP-Sepharose fraction was loaded at flow rate 0.2 ml/min. The protein-containing flow through fraction was collected, and
subsequently the matrix was washed (10 column volumes) with buffer D at
pH 7 supplemented with 50 mM KCl. The bound protein
fraction was eluted with a salt step (10 column volume of buffer D
supplemented with 2 M KCl). The nuclease activity was
identified (eluted during the 2 M KCl step) and pooled
(~0.750 µg of protein as determined by SDS-PAGE analysis and silver
staining, 5 ml). To optimize recovery of nuclease activity 0.1 mg/ml of
methylated bovine serum albumin (BSA) should be added during dialysis
to the pooled fraction of the 5'-AMP-Sepharose chromatographic step and
to the final 7-methyl-GTP fraction.
Analytical SMART Superdex 200 Gel Fitration--
The
poly(A)-Sepharose fraction (0.7 ml, 0.06 mg/ml protein) was first
concentrated by SMART MonoQ PC 1.6/5 (Amersham Pharmacia Biotech,
17-0671-01) chromatography by the following procedure. The column was
equilibrated by buffer D at pH 7 containing 50 mM KCl. The
poly(A)-Sepharose fraction was dialyzed against buffer D containing 50 mM KCl at pH 7 and applied to the MonoQ column at flow rate
50 µl/min. Bound material was eluted by increasing the KCl to 500 mM, and fraction size was 25 µl. Active fractions (total
volume, 100 µl) were identified and pooled. Subsequently, 50 µl of
the concentrated poly(A)-sepharose fraction was fractionated by gel
filtration using a SMART Superdex 200 PC 3.2/30 column equilibrated
with buffer D at pH 7 containing 100 mM KCl. Flow rate was
40 µl/min. Active fractions were identified by in vitro deadenylation. Molecular size markers were fractionated by the same
procedure on the Superdex 200 column. Molecular size markers were
ferritin, catalase, aldolase, and BSA having molecular masses 440, 232, 158, and 67 kDa, respectively. The 7-methyl-GTP-Sepharose fraction (50 µl) supplemented with methylated BSA (0.1 mg/ml) was loaded directly
onto a SMART Superdex 200 PC 3.2/30 column equilibrated in buffer D
supplemented with methylated BSA (0.1 mg/ml).
Preparation of RNA Substrates--
RNA substrates
L3(A30), L3(A30)X15,
L3(A30)X49,
L3(A30)X164 capped at the 5' end
were synthesized by in vitro transcription using T3 RNA
polymerases (Promega number P208C) and plasmid pT3L3(A30) (17), digested with NsiI, HincII,
EcoRI, and PvuII, respectively, as DNA template.
RNA substrates ML54(U30) and ML40(C32) were
prepared as described previously (17). RNA substrates
ML43(G14) and ML40(C16) were prepared as
described previously (17) using plasmid pT3ML43(G16), which
is identical to the previously described plasmid
pT3ML43(G30) with the exception of the number of inserted G
residues. RNA substrates were labeled either in their bodies or in
their homopolymeric tails by inclusion of radioactively labeled
mononucleotides during in vitro transcription as previously
outlined (17, 18). The specific radioactivities of the included
radioactive mononucleotides were 40 Ci/mmol in the transcription
mixture for body labeling or 5 Ci/mmol in the transcription mixture for
tail labeling. Transcribed RNA was purified according to Moore and
Sharp (30).
Assay Conditions--
Conditions for in vitro
deadenylation were 1-1.5 mM MgCl2, 2.5% (w/v)
poly(vinyl alcohol) (Sigma P-8136; molecular weight, 10,000), 100 mM KCl, 0.15 units of RNAguard, 5-20 fmol of RNA substrate, 10 mM HEPES-KOH, pH 7, 0.1 mM EDTA,
0.25 mM dithiothreitol, 10% glycerol, and the indicated
amount of protein fraction (18). The concentration of the nuclease
activity in the purest 5'-AMP/7-methyl-GTP fraction was approximately
100 units/ml. The RNA substrate was radioactively labeled as indicated.
Reaction volume was 15 or 25 µl, and incubations were performed at
30 °C. Reactions were terminated, and the reaction products were
investigated either by purifying the RNA and subsequent electrophoresis
in 10% polyacrylamide (19:1 acrylamide/bisacrylamide)/7 M
urea gels as described previously (17, 18) or by one-dimensional TLC
analysis (see below).
SDS-Polyacrylamide Gel Electrophoresis and Renaturation of
Nuclease Activity--
SDS-polyacrylamide (acrylamide:bisacrylamide
30:08) gels (5 and 7.5% acrylamide in spacer and separation gels,
respectively) were prepared according to Laemmli (31) using a
Mini-Protean II gel apparatus (Bio-Rad, 125BR). The indicated amount of
protein was fractionated directly on the gel or precipitated before
loading by the addition of 1 volume of 20% trichloroacetic acid
followed by centrifugation at 13,000 × g for 30 min at
4 °C. The obtained pellet was dried, washed with acetone, collected
again by centrifugation for 10 min at 13,000 × g, and
finally dissolved in 10 µl of sample buffer (50 mM
Tris-HCl, pH 6.8, 1% (w/v) SDS, 100 mM dithiothreitol, 8%
(v/v) glycerol, 0.025% (w/v) bromphenol blue), and separated by gel
electrophoresis. The resulting gel was fixed and stained as indicated.
Silver staining was according to Oakley et al. (32). Coomassie Brilliant Blue staining was according to standard protocol (33). Elution of proteins from SDS-polyacrylamide gel and renaturation of nuclease activity was done as described by Hager and Burgess (34).
In-gel Digestion and Mass Spectrometry Analysis--
The excised
band was prepared for and subjected to in-gel digestion as described
(35). In brief, after washing with ammonium bicarbonate and
acetonitrile, the gel piece was completely dried, and a solution
containing modified porcine trypsin, sequence grade (Promega Corp.
Madison, WI) was allowed to soak into the gel piece. After overnight
incubation at 30 °C, generated peptides were recovered by
extraction. The peptide mixture was analyzed by matrix-assisted laser
desorption ionization time of flight (MALDI-TOF) mass spectrometry, using a Bruker Biflex III instrument (Bremen, Germany), equipped with
delayed extraction and reflector. The sample was prepared by the dried
droplet technique, using a-cyano-4-hydroxycinnamic acid as matrix. The
instrument was externally calibrated using angiotensin II (MH+ 1046.54)
and adrenocorticotropic hormone fragment 18-39 (MH+ 2465.20). The
peptide mass fingerprinting analysis was done using ProFound (version
4.7.5).
Molecular Cloning and Expression--
The 74-kDa PARN
polypeptide and a 54-kDa fragment of PARN were molecularly cloned by a
standard reverse transcription-polymerase chain reaction procedure
followed by subcloning into the pGem T vector (Promega Inc.). Inserts
were subcloned into the pET-19 vector (Novagen Inc.) between the
NdeI and BamHI sites. The following primer pairs
were used 5'-TCGCATATGGAGATAATCAGGAGCA-3' and
5'-TCAGATCTTTACCATGTGTCAGGAACTTCA-3' for the 74-kDa PARN polypeptide
and 5'-TCGCATATGGAGATAATCAGGAGCA-3' and CGTGGATCCTCAGTTACCAAAGGCACTGAA
for the 54-kDa fragment. RNA template was obtained from HeLa
cells. Recombinant and His-tagged polypeptides were expressed in the
Escherichia coli strain BL21(DE3) and extracted according to
the manufacturer of the pET vectors. Extracted recombinant polypeptides
were purified by metal affinity chromatography using the TALON matrix
(CLONTECH Inc. number 8901) as outlined by the
manufacturer of the matrix.
Protein/Protein Cross-linking--
Bis(sulfosuccinimidyl)
suberate and dimethyl pimelimidate were purchased from Pierce, and
cross-linking was performed according to the instructions of the
manufacturer. Essentially, indicated amounts of purified recombinant
polypeptides, in buffer D at pH 8.2, were mixed with 10 mM
cross-linking reagents and incubated for 60 min at room temperature.
Total volume was 100 µl. The reactions were terminated by the
addition of 11 µl of 1 M Tris-HCl, pH 7.9.
Two-dimensional Thin Layer Chromatography--
Chromatography on
polyethyleneimine-cellulose F plates (Merck, number 5579) was performed
according to Konarska et al. (36). Liberated products from
deadenylation reactions were analyzed by two-dimensional TLC in
standard chambers using: 0.75 M
KH2PO4, pH 3.5 (H3PO4),
as first dimension solvent and isobutyric acid/concentrated NH4OH/H2O 577:38:385 (v/v) as second dimension
solvent. 5'-AMP (Sigma, A-1752), 2'-AMP (Sigma, A-9396), and 3'-AMP
(Sigma, A-0386) were included as markers. Position of markers were
detected by UV light (Mineralight lamp UVG-54, Ultra-Violet Products
Inc.). Radioactive molecules were detected by autoradiography or by 400 S PhosphorImager (Molecular Dynamics) analysis of the resulting polyethyleneimine-cellulose F plate.
One-dimensional TLC and Quantitation of Nuclease
Activity--
Deadenylation activity was quantified as follows:
L3(A30) RNA substrate labeled by inclusion of
[
-32P]ATP during in vitro transcription was
incubated in conditions for in vitro deadenylation as
described above with the addition of 0.1 mg/ml BSA. Reactions were
analyzed by one-dimensional TLC using 0.75 M
KH2PO4, pH 3.5 (H3PO4),
as the solvent. The resulting polyethyleneimine-cellulose F plate was
dried and scanned by a 400 S PhosphorImager (Molecular Dynamics). The
fraction of released [32P]AMP was determined. Knowing the
specific activity of [32P]AMP in the RNA substrate, the
amount of released AMP was calculated. One unit of deadenylation
activity was defined as the release of 1 µmol of AMP/min.
 |
RESULTS |
Partial Purification--
To purify a poly(A)-specific 3'
exonuclease activity, we used a dual assay strategy that monitored both
the disappearance of the RNA substrate and the appearance of the two
reaction products: deadenylated RNA and released AMP. Disappearance of
the RNA substrate and accumulation of the deadenylated product were
investigated by in vitro deadenylation using body labeled
L3(A30) RNA as the substrate, followed by analytical
polyacrylamide gel electrophoresis of the reacted RNA. Release of AMP
was investigated by in vitro deadenylation of
L3(A30) RNA substrate radioactively labeled in its poly(A)
tail followed by detection of released mononucleotides by TLC. An
important advantage of this dual assay strategy is that nucleases that
degrade both the poly(A) tail and the RNA body of the substrate can be excluded.
The poly(A)-specific 3' exonuclease activity was first partially
purified from calf thymus whole cell extract using ammonium sulfate
precipitation followed by four chromatographic steps (see "Experimental Procedures," Table I,
and Fig. 1). Using this purification protocol, a poly(A) removing activity fulfilling the requirements of
the dual assay strategy was purified approximately 14,000-fold (Table
I).
View this table:
[in this window]
[in a new window]
|
Table I
Purification of poly(A)-specific 3' exonuclease
Purification was monitored by the dual assay strategy and quantitated
as described under "Experimental Procedures." One unit is defined
as the release of 1 µmol of AMP/min. The numbers, protein (mg) and
activity (units), were obtained by multiplying the determined values by
four.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 1.
Fractionation scheme for purification of
poly(A)-specific 3' exonuclease isolated from calf thymus cell free
extract. See Table I and "Experimental Procedures" for
details.
|
|
The partially purified Blue-Sepharose fraction was further purified by
poly(A)-Sepharose affinity chromatography. This affinity step improved
the purity of the poly(A)-specific exonuclease activity approximately
14-fold. The protein profile of the obtained poly(A)-Sepharose fraction, as detected by SDS-PAGE, revealed several polypeptides (Fig.
2A). To determine whether any
of those was associated with the activity, we eluted them from the
SDS-PAGE gel matrix and subsequently denatured and renatured the eluted
polypeptides. Exonuclease activity specific for degrading poly(A) and
releasing AMP was recovered from polypeptides in the 50-60-kDa range
(Fig. 2B and data not shown), suggesting that a polypeptide
with this size was responsible for the poly(A)-specific 3' exonuclease
activity.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 2.
Renaturation of poly(A)-specific exonuclease
activity following SDS-PAGE. A, SDS-PAGE of proteins in
6 µl of the poly(A)-Sepharose 4B fraction (lane p(A)). The
resulting gel was stained by silver. Molecular mass markers were
separated in lane M. Numbers to the
left indicate molecular masses of marker proteins in kDa.
Capital letters (A-F) to the right
indicate relative positions of gel slices that were cut out from a
similar preparative gel in which 0.7 ml of the poly(A)-Sepharose 4B
fraction was fractionated. Proteins were eluted from the gel slices and
subsequently denatured and renatured (34). B, renatured
proteins isolated from gel slices A-F (see A)
were incubated together with uniformly labeled RNA substrate
L3(A30) under conditions for in vitro
deadenylation for 90 min. In each reaction 12 µl of renatured
proteins from a total volume of 1 ml of renatured protein was used.
Reacted RNA was recovered and fractionated by electrophoresis using a
10% polyacrylamide:bisacrylamide 19:1-7 M urea gel. The
resulting flourogram is shown. Arrows to the
right indicate the location of RNA substrate (S)
and product (P).
|
|
A 54-kDa Polypeptide Is Responsible for the Activity--
The
Blue-Sepharose fraction was further purified by two consecutive steps
of affinity chromatography, 5'-AMP-Sepharose followed by
7-methyl-GTP-Sepharose. SDS-PAGE of the final fraction revealed a
prominent 54-kDa polypeptide (Fig. 3).
Table I summarizes the quantitation of the purification. The two
million-fold purification is probably an overestimation because of the
presence of inhibitors of the activity in crude fractions. The increase
in total activity during purification is in agreement with the presence
of nuclease inhibitors. The nature of these nuclease inhibitors is at
present unknown. Some of them could very well be abundant RNA binding proteins because we (data not shown) and others (19, 21) have found
that addition of an increasing amount of poly(A)-binding protein
eventually will inhibit in vitro deadenylation.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
SDS-PAGE of proteins used for mass
spectrometry. Lane 7MeG, proteins (0.75 µg in 1.65 ml) in fraction 5'-AMP/7-methyl-GTP was precipitated and fractionated
by SDS-PAGE. The resulting gel was stained by silver. A gel slice
containing the 54-kDa protein (marked with an arrow) was cut
out from the gel and subsequently in-gel digested with trypsin. Tryptic
peptides were analyzed by MALDI-TOF mass spectrometry. Molecular mass
markers were separated in lane M. Numbers to the
right indicate molecular masses of marker proteins in
kDa.
|
|
The 54-kDa polypeptide was in-gel digested with trypsin and subjected
to mass spectrometry analysis using MALDI-TOF. The mass spectrum
revealed ten peptides that were used to scan the NCBI nonredundant data
base, using the application ProFound. Six of the ten peptides were
located in human PARN, and they represented the following tryptic
peptides of PARN, amino acids 87-99, 236-243, 260-272, 350-359,
414-421, and 444-454 (amino acids numbered according to Ref. 20). The
existence of the remaining four peptides is most likely explained by
differences between the human and bovine PARN amino acid sequences. We
conclude that the poly(A)-specific 3' exonuclease activity that we
purified was associated with a 54-kDa fragment of the 74-kDa PARN polypeptide.
Oligomeric Structure--
The 7-methyl-GTP-Sepharose fraction was
analyzed by gel filtration using a SMART Superdex 200 column as the
matrix. Active fractions were identified (Fig.
4A). The native molecular mass of the 54-kDa active fragment of PARN was estimated to 180-220 kDa.
The poly(A)-Sepharose fraction was also analyzed by SMART Superdex 200 chromatography. The native molecular size was also in this case
estimated to be 180-220 kDa. Both preparations of the 54-kDa active
fragment of PARN eluted consistently between the 158-kDa aldolase and
the 232-kDa catalase molecular size markers. The big discrepancy
between the molecular masses estimated by gel filtration and SDS-PAGE
suggests that the nuclease associated with the 54-kDa active fragment
of PARN is oligomeric. To further investigate the oligomeric structure
of the nuclease, we molecularly cloned and expressed recombinant human
74-kDa PARN polypeptide and human 54-kDa PARN fragment. The 74-kDa
polypeptide was found to be expressed in the soluble fraction of the
bacterial host, whereas the 54-kDa fragment was present in inclusion
bodies. The human 74-kDa PARN was affinity purified, and
poly(A)-specific nuclease activity was recovered (data not shown). The
purified recombinant human 74-kDa PARN nuclease was subjected to
protein/protein cross-linking using the homobifunctional cross-linkers
bis(sulfosuccinimidyl) suberate and dimethyl pimelimidate. The
cross-linked polypeptides were fractionated by SDS-PAGE and
subsequently revealed by either silver staining of the gel (data
not shown) or by Western blot analysis (Fig. 4B). The
addition of the homobifunctional cross-linkers shifted the
electrophoretic mobility of the 74-kDa polypeptide to two slower
migrating forms: II and III (Fig. 4B). A careful inspection
of the silver-stained gel (data not shown) revealed that none of the
visible contaminating bacterial proteins was shifted in contrast to the
74-kDa PARN polypeptide, which was quantitatively shifted to slower
migrating forms. Taken together these results strongly suggest that
forms II and III were generated by the formation of protein/protein
cross-links between two and three 74-kDa PARN polypeptides,
respectively. We conclude that the PARN nuclease is oligomeric and that
it most likely consists of three subunits (i.e.
homotrimer).

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 4.
The nuclease is oligomeric.
A, the 5'-AMP/7-methyl-GTP fraction was fractionated by
SMART Superdex 200 chromatography as described under "Experimental
Procedures." Obtained fractions (14-24) were incubated together with
uniformly labeled RNA substrate L3(A30) under conditions
for in vitro deadenylation for 120 min. In lane L the RNA
substrate was incubated with the 5'-AMP/7-methyl-GTP fraction. Reacted
RNA was recovered and fractionated by electrophoresis using a 10%
polyacrylamide:bisacrylamide 19:1-7 M urea gel. The
resulting flourogram is shown. Arrows to the
right denote the locations of RNA substrate (S)
and product (P). Arrows at the top
indicate the elution profile during SMART Superdex 200 chromatography
of the molecular mass markers. Molecular mass is given in kDa.
B, recombinant human 74-kDa PARN polypeptide (4 or 10 µg,
as indicated, in a 100-µl cross-linking reaction, respectively) was
treated with indicated homobifunctional cross-linkers
bis(sulfosuccinimidyl) suberate and dimethyl pimelimidate as outlined
under "Experimental Procedures" and fractionated by SDS-PAGE. The
gel was subsequently analyzed by Western blot analysis using a
His-tag-specific antiserum as the probe. The resulting flourogram is
shown. Arrows to the left indicate the positions
of forms I, II, and III. Numbers to the right
indicate the position of molecular size markers in kDa. S/S
denotes the boarder between the stacking and separation gels.
|
|
Conditions for in Vitro Deadenylation--
The conditions for
poly(A) tail removing activity were investigated by performing standard
in vitro deadenylation reactions using the poly(A)-Sepharose
fraction as the enzyme source and poly(A)-tailed labeled
L3(A30) RNA as the substrate. Activity was monitored by
following the release of mononucleotides by the one-dimensional TLC
assay. The requirements for monovalent (K+ and
Na+) and divalent (Mg2+, Mn2+,
Zn2+, and Ca2+) cations were investigated. We
found that monovalent cations were required and that the optimal
concentration was around 100 mM. Poly(A) removing activity
was higher in the presence of K+ than in the presence of
Na+. The nuclease activity was dependent on divalent
cations, and Mg2+ was found to be the preferred divalent
ion with an optimal concentration around 1 mM. The nuclease
was active in the presence of Mn2+. However, the activity
decreased to 17% of the nuclease activity detected in the presence of
Mg2+. No activity was detected in the presence of
Zn2+ or Ca2+. The optimal pH was found to be
around 7.
Substrate Specificity--
The RNA substrate specificity of the
poly(A) removing activity was investigated by three sets of
experiments. First, RNA substrates L3(A30),
ML54(U30), ML40(C32), and ML43(G14)
radioactively labeled in their RNA bodies were incubated in conditions
for in vitro deadenylation using either the
poly(A)-Sepharose fraction or the final 7-methyl-GTP fraction as the
source of enzyme. Reacted RNA was purified and analyzed by gel
electrophoresis (Fig. 5). It was found
that RNA substrate L3(A30) was efficiently degraded by the
3' exonuclease activity present in both tested fractions and that an
RNA product corresponding to the deadenylated RNA body accumulated
(Fig. 5A and data not shown). The RNA substrate ML54(U30) was degraded to some extent without the
accumulation of the RNA body (Fig. 5A), whereas RNA
substrates ML43(G14) and ML40(C32) were almost
unaffected by the 3' exonuclease activity in both fractions (Fig.
5A and data not shown). Secondly, the RNA substrate
specificity was investigated by incubating RNA substrates having
internal poly(A) stretches followed by plasmid encoded RNA sequences of
increasing length with either the poly(A)-Sepharose fraction or the
final 7-methyl-GTP fraction under conditions for in vitro
deadenylation. It was found that RNA substrates
L3(A30)X15, L3(A30)X49, and
L3(A30)X164 were almost unaffected
by the 3' exonuclease activity in both preparations in contrast to the
RNA substrate L3(A30), which was efficiently deadenylated
(Fig. 5B). Finally, RNA substrates L3(A30),
ML54(U30), ML40(C16), and ML43(G14)
radioactively labeled in their homopolymeric tails were incubated in
conditions for in vitro deadenylation using the
poly(A)-Sepharose fraction. The release of radioactive mononucleotides
was monitored by one-dimensional TLC assay. From this analysis we
determined the apparent Km and
Vmax values for each RNA substrate using
Lineweaver-Burk formalism. Table II
summarizes the obtained Km values and the calculated relative Vmax/Km values.
Interestingly, the Km values for the different
substrates were all in the 10 nM range, suggesting that
substrate specificity is related to the Vmax
parameter. Based on these three sets of experiments, we conclude that
the nuclease activity associated with the 54-kDa active fragment of PARN is highly specific for degrading poly(A) and that it
preferentially degrades 3' end-located poly(A) tails.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 5.
The 54-kDa fragment of the PARN nuclease is a
poly(A)-specific 3' exonuclease. The 5'-AMP/7-methyl-GTP fraction
(2 µl) was incubated under conditions for in vitro
deadenylation. Reacted RNA was purified and fractionated by
electrophoresis using a 10% polyacrylamide:bisacrylamide 19:1-7
M urea gel. The resulting flourogram is shown.
A, the reactions were incubated for 0, 3, 10, or 30 min, as
indicated, together with RNA substrate L3(54), L3(A30),
ML40(C32), ML43(G14), and
ML54(U30), as indicated. B, the reactions were
incubated for 0, 15, or 60 min, as indicated, together with RNA
substrate L3(A30), L3(A30)X15,
L3(A30)X49, and
L3(A30)X164, as indicated. Arrows to
the right denote the locations of RNA substrate
(S) and product (P).
|
|
5'-AMP Is the Released Mononucleotide--
The nature of the
released mononucleotide reaction product was investigated by
two-dimensional TLC. The poly(A)-Sepharose fraction or the final
7-methyl-GTP fraction was incubated, under condition for in
vitro deadenylation, together with RNA substrate L3(A30) radioactively labeled in its homopolymeric
adenosine tail. The reaction products were analyzed by two-dimensional
TLC using nonlabeled 2'-AMP, 3'-AMP, and 5'-AMP as markers. The result
(Fig. 6 and data not shown) showed that
the released mononucleotide comigrated with 5'-AMP. We conclude that
5'-AMP is a reaction product and that an exonuclease activity is
responsible for the degradation.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
The liberated reaction product during
deadenylation is 5'-AMP. The 5'-AMP/7-methyl-GTP fraction was
incubated under conditions for in vitro deadenylation
together with RNA substrate L3(A30), labeled by the
inclusion of [32-P] -ATP during in vitro
transcription. A fraction of the reaction was subjected to
two-dimensional TLC. The resulting autoradiogram of the dried
polyethyleneimine-cellulose plate is shown. The location of 2'-AMP,
3'-AMP, and 5'-AMP markers are indicated.
|
|
The Nuclease Activity Is Highly Processive--
To investigate
whether the nuclease activity degraded RNA substrates in a processive
or distributive fashion, we first titrated the exonuclease, using the
final 7-methyl-GTP-Sepharose fraction as the source of enzyme and the
RNA L3(A30) labeled in its body as the substrate.
Incubation time was 10 min. Fig.
7A (lanes 1-6) shows that nonreacted RNA substrate and fully deadenylated RNA product
were present when a low amount of exonuclease was added. Next, six
identical reactions using 2 µl of the 7-methyl-GTP fraction as the
exonuclease source were again incubated for 10 min, but in this case an
increasing amount of poly(A) was added to each reaction. Fig.
7A (lanes 7-12) shows that addition of poly(A) inhibited the reaction and that both nondeadenylated and completely deadenylated RNA substrates were present when the concentration of
poly(A) was 40 pg/µl or 0.4 ng/µl (lanes 10 and 11). The same results were obtained using the partially purified poly(A)-Sepharose fraction as the source of enzyme (data not shown). The concentration of
the RNA substrate in the experiments shown in Fig. 7A was
approximately 0.7 nM, which is below the
Km value of the RNA substrate. To investigate the
disappearance of the RNA substrate and the appearance of fully
deadenylated product at substrate concentration around the
Km value and at saturation, we increased the RNA
substrate concentration to 7 and 35 nM, respectively. We
used 2 µl of the 7-methyl-GTP fraction as the source of exonuclease and followed the time courses of these two reactions. The predictions for a highly processive exonuclease activity are: (i) the time point
for the appearance of the first fully deadenylated product should not
be affected by the RNA substrate concentration; (ii) unreacted RNA
substrate and fully deadenylated product should be present at some time
points; and (iii) a homogenous population of partially deadenylated RNA
substrates should not be visible. The result of this experiment is
shown in Fig. 7B. We conclude that the pattern of
degradation during these sets of experiments was consistent with a
highly processive exonuclease activity, i.e. the enzyme
catalyzes multiple rounds of digestion without dissociating from the
polymeric substrate.

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 7.
The nuclease activity is highly
processive. The 5'-AMP/7-methyl-GTP fraction was incubated with
RNA substrate L3(A30), labeled by the inclusion of
[32-P] -UTP during in vitro transcription,
in 25-µl reactions under conditions for in vitro
deadenylation. Reacted RNA was purified and fractionated by
electrophoresis in a gel containing 10% polyacrylamide:bisacrylamide
19:1-7 M urea. The resulting fluorograms are shown.
Arrows to the right denote the locations of RNA
substrate (S) and product (P). A, the
RNA substrate concentration was 0.7 nM, and reactions were
incubated for 10 min. Reactions fractionated in lanes 1-6
were performed in the presence of an increasing amount of the
5'-AMP/7-methyl-GTP fraction. The added amount was 0 µl
(lane 1), 0.1 µl (lane 2), 0.3 µl (lane
3), 1 µl (lane 4), 2 µl (lane 5), and 4 µl (lane 6) Reactions fractionated in lanes
7-12 were performed in the presence of 2 µl of the
5'-AMP/7-methyl-GTP fraction in an increasing amount of added poly(A).
The final concentrations of added poly(A) were 0 pg/µl (lane
7), 0.4 pg/µl (lane 8), 4 pg/µl (lane
9), 40 pg/µl (lane 10), 0.4 ng/µl (lane
11), and 4 ng/µl (lane 12). B, the RNA
substrate concentration was 7 nM (lanes 1-10)
and 35 nM (lanes 11-20) in the presence of 2 µl of the 5'-AMP/7-methyl-GTP fraction. Reactions were terminated
after 0 (lanes 1 and 11), 2 (lanes 2 and 12), 5 (lanes 3 and 13), 10 (lanes 4 and 14), 15 (lanes 5 and
15), 20 (lanes 6 and 16), 25 (lanes 7 and 17), 30 (lanes 8 and
18), 35 (lanes 9 and 19), and 40 (lanes 10 and 20) minutes. Lanes 1-10
and 11-20 were treated as two separate objects
(corresponding to two different exposure times using traditional
autoradiography) during PhosphorImager analysis to visualize RNA
substrate and deadenylated product. Thus, the relative darkness caused
by radioactivity in lanes 1-10 versus lanes 11-20 should
not be compared visually.
|
|
A Functional Link between the RNA 5' End Cap Structure and Poly(A)
Tail Removal--
The RNA substrate we have used during purification
was capped at its 5' end by the inclusion of
m7G(5')ppp(5')G cap analogue during in vitro
transcription of the L3(A30) RNA substrate. To investigate
whether the presence of a cap at the 5' end affected the nuclease
activity of the 54-kDa fragment of PARN, we compared the relative
specific activity of the nuclease using either capped or noncapped
L3(A30) RNA, radioactively labeled in their homopolymeric
tails, as the substrate. The released AMP was quantitated by the
one-dimensional TLC assay. We found that the specific activity was
approximately 6-fold higher using the capped L3(A30) RNA
substrate compared with the noncapped RNA substrate, suggesting that a
cap structure at the 5' end stimulated the poly(A) tail removing
activity of the 54-kDa fragment of PARN. To further investigate the
role of the cap during poly(A) tail removal, we added in
trans m7G(5')ppp(5')G, 5' GMP or 5'-AMP to in
vitro deadenylation reactions using capped L3(A30) RNA
as the substrate. Fig. 8 shows that the free m7G(5')ppp(5')G cap analogue severely inhibited the
deadenylation reaction already at 0.01 mM and completely
inhibited the reaction at 0.1 mM, whereas 5' GMP and 5'-AMP
only inhibited the reaction at much higher concentration. The efficient
inhibition of the nuclease activity by the cap analogue acting in
trans and the stimulatory role of the cap acting in cis
strongly suggest that the nuclease interacts with the cap structure
during poly(A) degradation establishing a functional link between
poly(A) tail removal at the 3' end and the cap structure at the 5' end
of the RNA substrate.

View larger version (107K):
[in this window]
[in a new window]
|
Fig. 8.
Inhibition of the poly(A)-specific 3'
exonuclease activity by addition of mononucleotides and cap
analogue. The 5'-AMP/7-methyl-GTP fraction (2 µl) was incubated
for 10 min with RNA substrate L3(A30), labeled by the
inclusion of [32-P] -UTP during in vitro
transcription, under conditions for in vitro deadenylation
in 25 µl of reaction volume. Reacted RNA was purified and
fractionated by electrophoresis in a gel containing 10%
polyacrylamide:bisacrylamide 19:1-7 M urea. The resulting
flourogram is shown. Arrows to the right denote
the locations of RNA substrate (S) and product
(P). Numbers above lanes denote
concentration of 5'-AMP, GMP, or m7G(5')ppp(5')G,
respectively (in mM). In lanes denoted
S RNA substrate was incubated without enzyme.
|
|
 |
DISCUSSION |
In this paper we report on the purification to apparent
homogeneity of a poly(A)-specific 3' exonuclease activity (17, 18) (Figs. 1-3 and 5 and Tables I and II). A 54-kDa polypeptide (Fig. 3)
corresponding to a fragment of the 74-kDa PARN nuclease (19, 20)
copurified with the 3' exonuclease activity. The molecular mass of the
nuclease, as determined by gel filtration, was found to be 180-220 kDa
(Fig. 4A). The purification of the poly(A)-specific 3'
exonuclease activity to apparent homogeneity is an important step
toward mechanistic studies of the native nuclease. This work will
therefore provide a solid platform for further studies using recombinant PARN nuclease as the source of activity.
The properties of the purified 54-kDa active fragment of PARN were
investigated and compared with a similar activity in HeLa cell free
extracts that we previously have identified (17, 18). Both activities
release 5'-AMP as the reaction product (Fig. 6), preferentially degrade
poly(A) (Table II and Fig. 5A), and can only efficiently
degrade poly(A) located at the 3' end of the RNA substrate (Fig.
5B). Both activities generate a deadenylated RNA body during
in vitro deadenylation (Fig. 5A), which upon
prolonged incubation eventually will be degraded (data not shown). Both activities are strictly dependent on divalent cations, preferentially Mg2+, for their activities. The two activities have very
similar chromatographic properties, and both can be purified by similar
purification protocols (data not shown). We have not managed to obtain
sufficient amount of the HeLa cell activity to unambigiously identify
the 54-kDa PARN polypeptide by SDS-PAGE and silver staining. We
conclude that the purified calf thymus poly(A) removing activity is a
poly(A)-specific 3' exonuclease and that it corresponds to the
poly(A)-specific 3' exonuclease activity that we previously identified
in HeLa cell-free extracts.
The N- and C-terminal ends of the 54-kDa active fragment of PARN have
not been unambigiously defined. However, we note that one of the
peptides in the MALDI-TOF mass spectrum, 1461.69 in molecular
weight, could correspond to the C-terminal end of the 54-kDa
PARN fragment. Four lines of evidence support this suggestion: (i) a
peptide of PARN consisting of amino acids 458-470 has the corresponding molecular weight; (ii) a lysine residue is located at
amino acid 457 of PARN, which should be expected after digestion with
trypsin; (iii) no peptide corresponding to predicted tryptic peptides
located C-terminally of amino acid 471 of PARN was identified in the
mass spectrum; and (iv) the calculated molecular mass of a predicted
polypeptide consisting of amino acids 1-470 of PARN is 54.2 kDa, which
corresponds to the molecular mass of the purified polypeptide, as
determined by SDS-PAGE analysis. It is noteworthy that a tentative
exonuclease domain belonging to the RNase D family of 3'-exonucleases
(28, 37) is located within the N-terminally located 389 amino acids of
human PARN (20).
We have investigated by Western blot analysis the presence of the
74-kDa PARN polypeptide in our fractions by using a polyclonal antibody
directed against the C-terminal part of the 74-kDa PARN polypeptide
(20) as the probe. Our data showed that large amount of the 74-kDa PARN
polypeptide was present in the initial crude extract. However, the
74-kDa polypeptide did not copurify with the nuclease activity we
selected based on our dual assay
strategy.2 A very low
abundant polypeptide in the size range of 80 kDa was visible in our
purest fraction (Fig. 3). We have not been able to confirm that this
polypeptide is related to the 74-kDa PARN polypeptide, neither by
Western blot analysis or mass spectrometry. Unfortunately, it is not
possible to investigate the presence of the 54-kDa polypeptide in the
cruder fractions by Western blot analysis because of the inability of
the antibody to recognize the 54-kDa PARN fragment. Thus, we cannot
rule out the possibility that the 54-kDa active fragment of PARN was
generated by proteolysis during purification. It is important to keep
this possibility in mind when interpreting several of the properties of
the nuclease activity that we have described in relation to the
nuclease activity associated with the 74-kDa PARN polypeptide. However,
high purity of an enzyme is a prerequisite for detailed mechanistic studies.
Körner et al. (20) detected two isoforms of PARN in
Xenopus oocytes, one being 74 kDa in molecular size and the
other 62 kDa. The 62-kDa form was the dominating form co-purifying with the nuclease activity after poly(A)-Sepharose chromatography. Interestingly, the two forms differed in subcellular distribution in
Xenopus oocytes; the 62-kDa form being cytoplasmic, whereas the 74-kDa form was nuclear. It is therefore possible that the 54-kDa
form that we purified represents an additional isoform of bovine PARN.
Further experiments are required to resolve this issue (see also below).
The development of in vitro systems and the characterization
of participating enzymes for polyadenylation and deadenylation will
make it possible to reveal mechanisms regulating the poly(A) tail
length. One interesting aspect is the competition between mRNA
poly(A) tail addition and removal (reviewed in Refs. 38 and 39). The
highly processive mode of degradation (Fig. 7) will definitely
influence this competition, because a highly processive nuclease will
compete very efficiently with the opposing poly(A) synthesis reaction
once degradation has been initiated. This is in sharp contrast to a
situation where a distributive nuclease activity will be competed by
the poly(A) synthesis reaction after removal of each single adenosine residue.
An intriguing possibility could be that the processive mode of
degradation is a unique property of the nuclease activity associated with the 54-kDa polypeptide of PARN because Körner et
al. (20) previously reported that the 74-kDa PARN nuclease
activity degraded poly(A) in a distributive fashion. Thus, the nuclease
activity associated with the 74-kDa PARN polypeptide that they purified differed in one important mechanistic aspect compared with the 54-kDa
PARN fragment activity. One reason for purifying two mechanistically distinct nuclease activities could be that different assay strategies were used to follow the nuclease activity during purification. Körner et al. (20) selected fractions for further
purification based on the release of mononucleotides, whereas we
selected fractions based on a dual assay strategy. This difference in
assay strategies could very well be responsible for preferentially
selecting a distributive nuclease activity in one case and a processive
nuclease activity in the other case.
Three lines of evidence suggests an interaction between the nuclease
associated with the 54-kDa active fragment of PARN and the mRNA cap
structure: (i) the specific activity of the nuclease is higher for
capped RNA substrate than for noncapped; (ii) a free cap analogue added
in trans inhibits the nuclease activity (Fig. 8); and (iii)
the nuclease activity interacts very strongly with the 7-methyl GTP
matrix, which partly resembles a methylated cap structure. This matrix
is frequently used to affinity purify cap binding proteins (40). All of
this evidence suggests that the 54-kDa fragment of PARN contains a
cap-binding site. The presence of a cap-binding site implies that the
54-kDa polypeptide interacts both with the 5' and the 3' end of the
mRNA during deadenylation. We can only speculate about the
functional importance of this interaction: (i) a physical interaction
between the cap structure and the poly(A) tail during deadenylation
will most likely interfere with the translational initiation process
(reviewed in Ref. 41); thus, the interaction may be part of a signal
that informs the translational machinery that the mRNA is subjected
to degradation and should not be used for protein translation; (ii) the
interaction between the cap and the poly(A) tail may play a role in
defining a deadenylation-dependent decapping pathway of RNA
degradation; (iii) the cap structure and the poly(A) tail may represent
two separate cis acting elements that together ensure that
the PARN nuclease preferentially selects polyadenylated mRNA as the
RNA substrate; and (iv) a physical interaction between the nuclease and
the cap structure may stabilize the enzyme/substrate complex. The cap
structure may therefore also play a role in making the 54-kDa PARN
fragment a highly processive nuclease.
 |
ACKNOWLEDGEMENTS |
We thank E. Bridge, L. Kirsebom, C. Kyriakopoulou, H. Nordvarg, U. Pettersson, and C. Phillips
for valuable suggestions and discussions throughout the completion of
this work. We are grateful to J. Hajdu, N. Henriksson, C. Ladenvall,
and P. Nilsson for helping us with the protein/protein cross-linking
experiments. We thank Drs. C. Körner and E. Wahle for the gift of
a PARN-specific antibody.
 |
Note added in Proof |
Interaction between PARN and the cap
structure has independently been observed by Gao et al.
(Gao, M., Fritz, D. T., Ford, L. P., and Wilusz, J. (2000) Mol.
Cell 5, 479-488) and Dehlin et al. (Dehlin, E.,
Wormington, M., Körner. C. G., and Wahle, E. (2000) EMBO J. 19, 1079-1086)
 |
FOOTNOTES |
*
This work was supported by the Swedish Natural Science
Research Council, the Swedish Strategic Research Foundation, the
European Commission program, and the Marcus Borgströms
Foundation at Uppsala University.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
**
To whom correspondence should be addressed. Tel.: 46-18-471-49-08;
Fax: 46-18-50-80-95; E-mail: anders.virtanen@icm.uu.se.
Published, JBC Papers in Press, May 8, 2000, DOI 10.1074/jbc.M001705200
2
J. Martinez, Y.-G. Ren, and A. Virtanen,
unpublished observation.
 |
ABBREVIATIONS |
The abbreviations used are:
PARN, poly(A)-specific ribonuclease;
PAGE, polyacrylamide gel
electrophoresis;
BSA, bovine serum albumin;
MALDI-TOF, matrix-assisted
laser desorption ionization time of flight.
 |
REFERENCES |
| 1.
|
Ross, J.
(1995)
Microbiol. Rev.
59,
423-450
|
| 2.
|
Beelman, C. A.,
and Parker, R.
(1995)
Cell
81,
179-185
|
| 3.
|
Caponigro, G.,
and Parker, R.
(1996)
Microbiol. Rev.
60,
233-249
|
| 4.
|
Mitchell, P.,
Petfalski, E.,
Shevchenko, A.,
Mann, M.,
and Tollervey, D.
(1997)
Cell
91,
457-466
|
| 5.
|
van Hoof, A.,
and Parker, R.
(1999)
Cell
99,
347-350
|
| 6.
|
Allmang, C.,
Kufel, J.,
Chanfreau, G.,
Mitchell, P.,
Petfalski, E.,
and Tollervey, D.
(1999)
EMBO J.
18,
5399-5410
|
| 7.
|
Jacobs-Anderson, J. S.,
and Parker, R.
(1998)
EMBO J.
17,
1497-1506
|
| 8.
|
Shaw, G.,
and Kamen, R.
(1986)
Cell
46,
659-667
|
| 9.
|
Couttet, P.,
Fromont-Racine, M.,
Steel, D.,
Pictet, R.,
and Grange, T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5628-5633
|
| 10.
|
Brewer, G.,
and Ross, J.
(1988)
Mol. Cell. Biol.
8,
1697-1708
|
| 11.
|
Brewer, G.
(1998)
J. Biol. Chem.
273,
34770-34774
|
| 12.
|
Ford, L. P.,
Bagga, P. S.,
and Wilusz, J.
(1997)
Mol. Cell. Biol.
17,
398-406
|
| 13.
|
Ford, L. P.,
Watson, J.,
Keene, J. D.,
and Wilusz, J.
(1999)
Genes Dev.
13,
188-201
|
| 14.
|
Ross, J.,
and Kobs, G.
(1986)
J. Mol. Biol.
188,
579-593
|
| 15.
|
Virtanen, A.,
and Åström, J.
(1997)
in
Prog. Mol. Subcell. Biol.
(Jeanteur, Ph., ed), Vol. 16
, pp. 199-220, Springer-Verlag, Berlin
|
| 16.
|
Bachmann, M.,
Schröder, H. C.,
Messer, R.,
and Müller, W. E. G.
(1984)
FEBS Lett.
171,
25-30
|
| 17.
|
Åström, J.,
Åström, A.,
and Virtanen, A.
(1991)
EMBO J.
10,
3067-3071
|
| 18.
|
Åström, J.,
Åström, A.,
and Virtanen, A.
(1992)
J. Biol. Chem.
267,
18154-18159
|
| 19.
|
Körner, C. G.,
and Wahle, E.
(1997)
J. Biol. Chem.
272,
10448-10456
|
| 20.
|
Körner, C. G.,
Wormington, M.,
Muckenthaler, M.,
Schneider, S.,
Dehlin, E.,
and Wahle, E.
(1998)
EMBO J.
17,
5427-5437
|
| 21.
|
Wormington, M.,
Searfoss, A. M.,
and Hurney, C. A.
(1996)
EMBO J.
15,
900-909
|
| 22.
|
Caruccio, N.,
and Ross, J.
(1994)
J. Biol. Chem.
269,
31814-31821
|
| 23.
|
Sachs, A. B.,
and Davis, R. W.
(1989)
Cell
58,
857-867
|
| 24.
|
Sachs, A. B.,
and Deardorff, J. A.
(1992)
Cell
70,
961-973
|
| 25.
|
Lowell, J. E.,
Rudner, D. Z.,
and Sachs, A. B.
(1992)
Genes Dev.
6,
2088-2099
|
| 26.
|
Boeck, R.,
Tarun, S.,
Rieger, M.,
Deardorff, J. A.,
Müller-Auer, S.,
and Sachs, A. B.
(1996)
J. Biol. Chem.
271,
432-438
|
| 27.
|
Brown, C. E., Jr.,
S., Z. T.,
Boeck, R.,
and Sachs, A. B.
(1996)
Mol. Cell. Biol.
16,
5744-5753
|
| 28.
|
Moser, M. J.,
Holley, W. R.,
Chatterjee, A.,
and Mian, I. S.
(1997)
Nucleic Acids Res.
25,
5110-5118
|
| 29.
|
Wahle, E.
(1991)
J. Biol. Chem.
266,
3131-3139
|
| 30.
|
Moore, C. L.,
and Sharp, P. A.
(1985)
Cell
41,
845-855
|
| 31.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685
|
| 32.
|
Oakley, B. R.,
Kirsch, D. R.,
and Morris, R.
(1980)
Anal. Biochem.
105,
361-363
|
| 33.
|
Merryl, C. R.
(1990)
Methods Enzymol.
182,
477-488
|
| 34.
|
Hager, D. A.,
and Burgess, R. R.
(1980)
Anal. Biochem
109,
76-86
|
| 35.
|
Hellman, U.
(1997)
in
Protein Structure Analysis: Preparation, Characterization, and Microsequencing
(Kamp, R. M.
, Choli-Papadopoulou, T.
, and Wittman-Liebold, B., eds)
, pp. 97-104, Springer-Verlag, Heidelberg
|
| 36.
|
Konarska, M. M.,
Grabowski, P. J.,
Padgett, R. A.,
and Sharp, P. A.
(1985)
Nature
313,
552-557
|
| 37.
|
Mian, I. S.
(1997)
Nucleic Acids Res.
25,
3187-3195
|
| 38.
|
Richter, J. D.
(1999)
Microbiol. Mol. Biol. Rev.
63,
446-456
|
| 39.
|
Wickens, M.
(1990)
Trends Biochem. Sci.
15,
320-324
|
| 40.
|
Morino, S.,
Hazama, H.,
Ozaki, M.,
Teraoka, Y.,
Shibata, S.,
Doi, M.,
Ueda, H.,
Ishida, T.,
and Uesugi, S.
(1996)
Eur. J. Biochem.
239,
597-601
|
| 41.
|
Sachs, A. B.,
Sarnow, P.,
and Hentze, M. W.
(1997)
Cell
89,
831-838
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike